地特胰岛素联合伏格列波糖对门诊初诊老年2型糖尿病的疗效及安全性

Clinical efficacy and safety of insulin detemir combined with voglibose in elderly outpatients with newly diagnosed type 2 diabetes mellitus patients

目的探讨地特胰岛素联合伏格列波糖对门诊初诊老年2型糖尿病患者的疗效及安全性。方法 60例患者随机分两组,治疗组采用地特胰岛素联合伏格列波糖,对照组采用精蛋白锌重组赖脯胰岛素50R;16周后,比较两组空腹血糖、餐后2h血糖、血糖波动程度、糖化血红蛋白(HbA1c)、低血糖发生率、体重、血脂变化。结果两组均可有效地控制血糖、HbA1c(P<0.01),组间降低幅度比较,差异无统计学意义(P>0.05);但治疗组在血糖波动程度、低血糖发生率、体重增加方面均优于对照组(P<0.05)。两组治疗后的血脂均较治疗前改善,但差异无统计学意义(P>0.05)。结论地特胰岛素联合伏格列波糖可安全、有效、平稳地控制老年2型糖尿病患者的血糖,低血糖发生率及体重增加较少,患者满意度高。

Objective To investigate the clinical efficacy and safety of insulin detemir combined with voglibose in elderly outpatients with newly diagnosed type 2 diabetes mellitus. Methods Sixty cases of newly diagnosed elderly outpatients with type 2 diabetes mellitus were randomly divided into two groups,observation group treated with subcutaneous injection of insulin detemir combined with oral vogliboseand control group treated with subcutaneous injection of Humalog Mix50.FPG,2hPG,HbAlc,blood glucose fluctuations,the incidence of hypoglycemia,increase of bodyweight,lipid were determined and compared between two groups after treatment for 16-weeks. Results After 16-weeks＇treatment,the levels of FPG,2hPG and HbAlc were descended significantly in both groups（P〈0.01）,and no significant differences between two groups（P〉0.05）. However,observation group presents significantly lower incidence of hypoglycemia, blood glucose fluctuations and increase of bodyweight than of control group（P〈0.05）. After treatment, the level of lipid was improved without statistical significance. Conclusions Blood glucose can be safely,effectively and steadily controlled by insulin detemir combined with voglibose therapy in elderly outpatients with newly diagnosed T2DM. Moreover,insulin detemir combined with voglibose has lower incidence of hypoglycemia,less increase of bodyweight.